GLOBE LIFE INC. quarterly report, Q2 FY2018

Business context and reporting period

This is Torchmark Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2018, filed August 7, 2018. The filing describes a life and supplemental health insurer; the supplied filing is under the Torchmark name, although the request identifies Globe Life Inc.

Financial performance and position

Amounts below are in millions of dollars except per-share data. Comparisons are with the corresponding 2017 period; balance-sheet comparisons are with December 31, 2017.

MetricQ2 2018Six months 2018Comparable 2017
Total revenue$1,084.8$2,155.2$1,029.1 Q2; $2,052.7 six months
Income before tax$226.9$439.7$201.9 Q2; $393.7 six months
Net income$184.4$358.0$140.3 Q2; $273.8 six months
Diluted earnings per share$1.59$3.08$1.18 Q2; $2.29 six months
Operating cash flowNot stated separately$616.5$739.1 six months
  • Six-month premiums increased 4% to $1,704.1 million; life premiums rose 4% to $1,200.8 million and health premiums 3% to $503.2 million. Net investment income increased 4% to $436.7 million.
  • Six-month underwriting margins were $316.0 million for life (up 8%; 26% of premium), $117.6 million for health (up 8%; 23% of premium), and $5.2 million for annuities (down 1%). Excess investment income was $121.9 million, up 1%; per diluted share it rose 4% to $1.05.
  • Insurance administrative expenses increased 7.2% to $110.7 million and rose to 6.5% of premium from 6.3%. Interest expense increased to $44.0 million from $41.9 million.
  • At June 30, total assets were $22,878.7 million, shareholders’ equity $5,571.6 million, and total debt approximately $1,489.1 million. Debt comprised $671.7 million short-term and $817.5 million long-term.
  • Cash and short-term investments were approximately $150.8 million, versus $245.6 million at year-end. Cash declined $36.3 million during the six months; investing activities used $409.2 million and financing activities used $251.0 million.
  • Shareholders’ equity fell $659.8 million from year-end, primarily reflecting $820.8 million of after-tax other comprehensive losses, including unrealized investment losses, partly offset by $358.0 million net income. The fixed-maturity portfolio’s net unrealized gain declined to $934.5 million from $1,974.2 million.

Material changes versus the prior period

  • Six-month net income increased 31% and diluted EPS increased 34%; management attributed the largest contribution to the lower corporate tax rate enacted in 2017, from 35% to 21%. Net operating income, a non-GAAP measure, rose 24% to $347.2 million.
  • Six-month operating cash flow declined $122.5 million, primarily due to lower discontinued-operations cash flow and timing fluctuations in settlements included in other liabilities.
  • The company repurchased 2.0 million shares using parent-company excess cash flow for $174.4 million at an average $85.41 per share; total treasury-share purchases, including option-exercise proceeds, were $206.6 million.
  • Interest-rate increases reduced the fixed-maturity portfolio’s fair value and GAAP equity. Management reported no other-than-temporary impairments in the 2018 period.

Outlook, commentary, risks and contingencies

  • No formal earnings guidance is provided. Management expected life direct-response sales declines to moderate during the rest of 2018, and projected approximately $440 million of insurance-subsidiary dividends to the parent and approximately $325 million of parent excess cash flow for the full year.
  • Management estimated the 2018 consolidated risk-based capital ratio could be 275%–285% before additional capital contributions; reaching a 300%–325% target could require $100 million–$225 million of additional subsidiary capital. It said this could be funded through debt or parent liquidity and did not expect a significant net-income impact.
  • Management cited low reinvestment yields as a constraint on investment-income growth. It expected fixed-maturity turnover of 2%–3% annually over the next five years and stated the portfolio could absorb an approximately 50–55 basis-point rate increase before eliminating its net unrealized gains. It said it had the ability and intent to hold temporarily impaired securities to maturity.
  • Risks include changes in policy sales and lapses, mortality and health-care utilization, regulation and Medicare alternatives, interest rates and credit quality, pricing competition, litigation, premium-rate approvals, operating efficiency, customer response, and cybersecurity or data-access events.
  • Routine litigation and unclaimed-property audits were not expected by management to have a material adverse effect. A putative sales-agent wage class action against American Income Life was filed in February 2018; the court granted the company’s motion to compel arbitration on July 27, 2018. The company stated that a material adverse judgment in current litigation was considered remote and did not estimate a loss range for reasonably possible unaccrued contingencies.
  • The $750 million credit facility (with possible extension to $1 billion) matures in May 2021. Commercial paper outstanding was $375.2 million at a 2.61% annualized rate; $155 million of letters of credit were outstanding and reported remaining facility availability was $219.8 million. The company reported compliance with capitalization covenants.
  • The company early adopted a standard permitting reclassification of $252 million of tax effects from accumulated other comprehensive income to retained earnings in 2017. It reported that the 2017 tax-reform accounting estimate remained unchanged at June 30 and expected to complete its analysis in the fourth quarter of 2018.

Important facts for investors to verify

  1. Confirm the issuer and security identity: this supplied filing is for Torchmark Corporation, despite the request’s Globe Life Inc. label.
  2. Assess the extent to which earnings growth reflects the tax-rate reduction, rather than underlying operating improvement; review both GAAP income and non-GAAP net operating income.
  3. Track capital adequacy and whether the potential $100 million–$225 million subsidiary contribution is made, including its funding source and effect on debt.
  4. Monitor cash generation, commercial-paper levels and available credit, alongside the substantial decline in cash and short-term investments.
  5. Review investment portfolio credit quality, unrealized losses and interest-rate sensitivity; distinguish market-value changes from realized credit losses.
  6. Follow sales trends by distribution channel, particularly direct-response life sales, and administrative-cost growth.